Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand (Nasdaq: LGND) will report third quarter 2025 financial results on Thursday, November 6, 2025. A conference call will begin at 8:30 AM Eastern Time to discuss results and provide a business update.
Investors can join by phone in the U.S. and Canada at (800) 715-9871 or internationally at (646) 307-1963 using Conference ID 3661098. A live webcast and replay will be available via the company webcast link.
Ligand (Nasdaq: LGND) will hold its annual Investor Day on December 9, 2025 in New York City at The Harvard Club from 10:30 a.m. to 12:00 p.m. ET. Management presentations will include CEO Todd Davis and CFO Tavo Espinoza and will cover the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook.
Guest speaker Scott Plesha, CEO of partner Pelthos Therapeutics, will discuss the recent launch of ZELSUVMI (berdazimer) topical gel 10.3%, described as the first FDA-approved at-home treatment for molluscum contagiosum. A live webcast and replay will be available on Ligand’s investor relations website, and investors can register for the event online.
Ligand (Nasdaq: LGND) said partner SQ Innovation received FDA approval on October 9, 2025 for Lasix ONYU (furosemide injection), a drug‑device combo enabling subcutaneous, at‑home treatment of edema in adults with chronic heart failure.
Lasix ONYU is a high‑concentration furosemide formulation (80mg/2.67mL; 30mg/mL) using Captisol and pairs with a reusable Infusor (48 treatments) plus a sterile single‑use cartridge. Captisol is cited as a key enabler and this is the 17th Captisol‑enabled product. Ligand holds exclusive Captisol license/supply terms with SQ Innovation signed in 2019 and will receive milestone payments, a low‑single‑digit royalty, and material sales revenue. SQ Innovation expects product availability in Q4 2025.
Ligand Pharmaceuticals (Nasdaq: LGND) announced its participation in two upcoming investor conferences in September 2025. CEO Todd Davis and CFO Tavo Espinoza will attend the Citi 20th Annual BioPharma Conference in Boston on September 3, participating in a fireside chat at 11:15 a.m. ET. The management team will also present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9 at 1:00 p.m. ET.
During both conferences, management will be available for one-on-one meetings with investors and attendees through their respective conference representatives.
Ligand Pharmaceuticals (Nasdaq: LGND) has successfully completed its offering of 0.75% convertible senior notes due 2030, raising a total principal amount of $460.0 million. The company generated net proceeds of approximately $445.1 million after deducting fees and expenses.
The company allocated $45.9 million for convertible note hedge transactions and used $15.0 million to repurchase 102,034 shares at $147.01 per share. To manage potential dilution, Ligand entered into warrant transactions with a strike price of $294.02 per share, representing a 100% premium over the last reported share price.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced the pricing of $400 million convertible senior notes due 2030 in a private placement to qualified institutional buyers. The notes will carry a 0.75% annual interest rate, payable semiannually, with an initial conversion price of $194.79 per share, representing a 32.5% premium over the current stock price.
The company expects net proceeds of $386.9 million (or $445.1 million if the initial purchasers exercise their option). Ligand will use $39.9 million for convertible note hedge transactions, $15.0 million to repurchase 102,034 shares of common stock, and the remainder for general corporate purposes. The notes include provisions for conversion, redemption, and repurchase under specific conditions.
Ligand Pharmaceuticals (Nasdaq: LGND) announced plans to offer $400 million of convertible senior notes due 2030 in a private placement to qualified institutional buyers. The company will also grant initial purchasers a 13-day option to buy up to $60 million in additional notes.
The notes will be senior unsecured obligations with semiannual interest payments starting April 1, 2026. Upon conversion, Ligand will pay cash up to the principal amount and may settle the remainder in cash, stock, or a combination. The company plans to use the proceeds for convertible note hedge transactions, up to $30 million for share repurchases, and general corporate purposes including potential business investments.
To manage dilution, Ligand will enter into convertible note hedge and warrant transactions with option counterparties, though the warrant transactions could have a dilutive effect if the stock price exceeds the warrant strike price.
Ligand Pharmaceuticals (Nasdaq: LGND) reported strong Q2 2025 financial results and raised its full-year guidance. Total revenue reached $47.6 million, up 15% year-over-year, driven by a 57% increase in royalty revenue to $36.4 million. The company raised its 2025 guidance, now expecting total revenue of $200-225 million and adjusted EPS of $6.70-7.00.
Key highlights include the completion of the Pelthos Therapeutics merger, a $40 million strategic investment in Orchestra BioMed, and the commercial launch of Zelsuvmi. The company maintains a strong financial position with $245 million in cash and investments, including $26.5 million in Viking Therapeutics stock.
Ligand Pharmaceuticals (NASDAQ:LGND) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host a conference call and webcast at 8:30 AM ET to discuss the quarterly performance and provide a business update.
Investors can access the call via phone at (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (International) using Conference ID 3661098. A live webcast and replay will also be available through the company's website.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Pelthos Therapeutics (NYSE American: PTHS) has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum. The launch triggered a $5 million milestone payment to Ligand.
Following Pelthos' merger with Channel Therapeutics, Ligand now owns 56% of Pelthos. The agreement includes a 13% royalty on worldwide ZELSUVMI sales and potential for additional $5 million in commercial sales milestones.